

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

LOAN FACILITIES WITH CHINA DEVELOPMENT BANK - ANNOUNCEMENT PURSUANT TO RULE 13.18 OF THE LISTING RULES

The Board announces that the Company as borrower entered into two additional facility agreements with China Development Bank Corporation Hong Kong Branch for a HK\$300,000,000 guaranteed term-loan facility and a HK\$300,000,000 unsecured term-loan facility respectively. The principal amount under the Facilities shall be repaid in full after the expiry of a 35 months term and a 33 months term respectively from the relevant utilization date.

Pursuant to the Agreement, if there occurs a change of control of the Company, the Lender may (i) cancel the commitment under the respective Facilities, and (ii) declare all outstanding loans under the respective Facilities, together with accrued interest and all other amounts accrued thereunder, to be immediately due and payable.

This announcement is made pursuant to Rule 13.18 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

Reference is made to the announcement of The United Laboratories International Holdings Limited (the “**Company**”) dated 14 June 2013 in relation to a HK\$800,000,000 three year term-loan facility (the “**Three Year Term-Loan Facility**”) with China Development Bank Corporation Hong Kong Branch (the “**Lender**”).

The board of directors (the “**Board**”) of the Company announces that the Company as borrower entered into two additional facility agreements (the “**Agreements**”) with the Lender for a HK\$300,000,000 guaranteed term-loan facility (the “**Guaranteed Term-Loan Facility**”) and a HK\$300,000,000 unsecured term-loan facility (the “**Unsecured Term-Loan Facility**”) respectively. The principal amount under the Guaranteed Term-Loan Facility and the Unsecured Term-Loan Facility (together, the “**Facilities**”) shall be repaid in full after the expiry of a 35 months term and a 33 months term respectively from the relevant utilization date.

Pursuant to the Agreements, if there occurs a change of control of the Company, the Lender may (i) cancel the commitment under the respective Facilities, and (ii) declare all outstanding loans under the respective Facilities, together with accrued interest and all other amounts accrued thereunder, to be immediately due and payable. Pursuant to the Agreements, (i) a “change of control” occurs if any

person or group of persons acting in concert (as defined under the Hong Kong Codes of Takeovers and Merger and Share Repurchases), other than the person or group of persons who currently have control, gains control of the Company; and (ii) “control” means the power to exercise or control the exercise of 50 per cent. or more of the voting power at general meetings of the Company, or to control the composition of the majority of the Board, whether through the ownership of voting capital, by contract or otherwise.

As at the date of this announcement, the Company’s aggregate level of facility with the Lender under the Three Year Term-Loan Facility, Guaranteed Term-Loan Facility and the Unsecured Term-Loan Facility is HK\$1,400,000,000.

As at the date of this announcement, (i) Nautilus Trustees Asia Limited (formally known as DBS Trustee H.K. (Jersey) Limited) (as the trustee of The Choy Family Trust), through its wholly-owned subsidiaries, Gesell Holdings Limited and Heren Far East Limited and ; (ii) Ms. Ning Kwai Chun, Mr. Tsoi Hoi Shan and Ms. Choy Siu Chit (all being members of the Choy family), are collectively holding 1,075,651,000 shares of the Company, representing approximately 66.12% of the issued share capital of the Company.

The Company will continue to comply with the disclosure obligations under Rule 13.21 of the Listing Rules for so long as circumstance giving rise to the above obligation continue to exist.

By Order of the Board
**The United Laboratories
International Holdings Limited**
Tsoi Hoi Shan
Chairman

Hong Kong, 13 January 2015

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Ms. Zou Xian Hong, Ms. Zhu Su Yan and Mr. Fang Yu Ping as executive directors; and Mr. Chong Peng Oon, Mr. Huang Bao Guang, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.